For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
0
views
13
references
 Top references
cited by
0
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      107
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Real-World Experience With Maribavir for Treatment of Cytomegalovirus Infection in High-Risk Solid Organ Transplant Recipients

      brief-report

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          We evaluated use of maribavir (MBV) for treatment of 15 episodes of refractory/resistant cytomegalovirus infection in 13 solid organ transplant recipients. Treatment failure due to treatment-emergent MBV resistance or early virological recurrence after MBV discontinuation occurred in 7 (47%) episodes. Sustained viral clearance was achieved in 6 (40%) episodes.

          Related collections

          Most cited references13

          • Record: found
          • Abstract: found
          • Article: found

          Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials.

          David R. Snydman, Per Ljungman, Michael Boeckh … (2016)
          Cytomegalovirus (CMV) infection and disease are important causes of morbidity and mortality in transplant recipients. For the purpose of developing consistent reporting of CMV outcomes in clinical trials, definitions of CMV infection and disease were developed and most recently published in 2002. Since then, there have been major developments in its diagnosis and management. Therefore, the CMV Drug Development Forum consisting of scientists, clinicians, regulators, and industry representatives has produced an updated version incorporating recent knowledge with the aim to support clinical research and drug development. The main changes compared to previous definitions are the introduction of a "probable disease" category and to incorporate quantitative nucleic acid testing in some end-organ disease categories. As the field evolves, the need for updates of these definitions is clear, and collaborative efforts between scientists, regulators, and industry can provide a platform for this work.
          Article 0 comments Cited 188 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Cytomegalovirus in solid organ transplant recipients—Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice

            Raymund R Razonable, Atul Humar (2019)
            Article 0 comments Cited 155 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Maribavir for Refractory or Resistant Cytomegalovirus Infections in Hematopoietic-cell or Solid-organ Transplant Recipients: A Randomized, Dose-ranging, Double-blind, Phase 2 Study

              Genovefa Papanicolaou, Fernanda P Silveira, Amelia A Langston … (2018)
              In this multicenter, dose-ranging study of maribavir for the treatment of cytomegalovirus (CMV) infections deemed refractory or resistant to current antivirals, 67% of patients achieved clearance of CMV viremia within 6 weeks, with responses maintained for up to 24 weeks.
              Article 0 comments Cited 60 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Contributors
                Bin Ni:
                ORCID: https://orcid.org/0000-0001-7148-4653
                Cameron R Wolfe
                Sana Arif
                Manuela Carugati:
                ORCID: https://orcid.org/0000-0002-3187-5905
                Madeleine R Heldman:
                ORCID: https://orcid.org/0000-0002-9424-1870
                Julia A Messina:
                ORCID: https://orcid.org/0000-0001-6411-198X
                Rachel A Miller
                Jennifer L Saullo:
                ORCID: https://orcid.org/0000-0002-7684-431X
                Arthur W Baker:
                ORCID: https://orcid.org/0000-0002-0914-0291
                Eileen K Maziarz:
                ORCID: https://orcid.org/0000-0001-7779-9605
                Journal
                Journal ID (nlm-ta): Open Forum Infect Dis
                Journal ID (iso-abbrev): Open Forum Infect Dis
                Journal ID (publisher-id): ofid
                Title: Open Forum Infectious Diseases
                Publisher: Oxford University Press (US )
                ISSN (Electronic): 2328-8957
                Publication date Collection: July 2024
                Publication date (Electronic): 15 June 2024
                Publication date PMC-release: 15 June 2024
                Volume: 11
                Issue: 7
                Electronic Location Identifier: ofae335
                Affiliations
                Division of Infectious Diseases, Duke University School of Medicine , Durham, North Carolina, USA
                Division of Infectious Diseases, Duke University School of Medicine , Durham, North Carolina, USA
                Division of Infectious Diseases, Duke University School of Medicine , Durham, North Carolina, USA
                Division of Infectious Diseases, Duke University School of Medicine , Durham, North Carolina, USA
                Division of Infectious Diseases, Duke University School of Medicine , Durham, North Carolina, USA
                Division of Infectious Diseases, Duke University School of Medicine , Durham, North Carolina, USA
                Division of Infectious Diseases, Duke University School of Medicine , Durham, North Carolina, USA
                Division of Infectious Diseases, Duke University School of Medicine , Durham, North Carolina, USA
                Division of Infectious Diseases, Duke University School of Medicine , Durham, North Carolina, USA
                Division of Infectious Diseases, Duke University School of Medicine , Durham, North Carolina, USA
                Author notes
                Correspondence: Bin Ni, MD, PhD, Division of Infectious Diseases, Duke University Medical Center, 315 Trent Drive, Hanes House, Durham, NC 27710 ( bin.ni@ 123456duke.edu ); Eileen K. Maziarz, MD, Division of Infectious Diseases, Duke University Medical Center, 315 Trent Drive, Hanes House, Durham, NC 27710 ( eileen.maziarz@ 123456duke.edu ).

                Potential conflicts of interest. All authors: No reported conflicts.

                Author information
                https://orcid.org/0000-0001-7148-4653
                https://orcid.org/0000-0002-3187-5905
                https://orcid.org/0000-0002-9424-1870
                https://orcid.org/0000-0001-6411-198X
                https://orcid.org/0000-0002-7684-431X
                https://orcid.org/0000-0002-0914-0291
                https://orcid.org/0000-0001-7779-9605
                Article
                Publisher ID: ofae335
                DOI: 10.1093/ofid/ofae335
                PMC ID: 11218774
                PubMed ID: 38957689
                SO-VID: a573ac75-8c5c-4762-b7a4-ec908c9199b6
                Copyright © © The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
                License:

                This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence ( https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.

                History
                Date received : 20 March 2024
                Date: 06 June 2024
                Date accepted : 13 June 2024
                Date: 02 July 2024
                Page count
                Pages: 5
                Funding
                Funded by: National Institute of Allergy and Infectious Diseases, DOI 10.13039/100000060;
                Funded by: National Institutes of Health, DOI 10.13039/100000002;
                Award ID: K08-AI163462
                Categories
                Subject: Infectious Diseases in Special Populations
                Subject: Brief Report
                Subject: AcademicSubjects/MED00290

                Keywords: cytomegalovirus,maribavir,solid organ transplantation,antiviral drug resistance,antiviral therapy
                Data availability:
                Keywords: cytomegalovirus, maribavir, solid organ transplantation, antiviral drug resistance, antiviral therapy

                Comments

                Comment on this article